644 related articles for article (PubMed ID: 21292811)
1. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
2. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
Wang L; Fan J; Thompson LF; Zhang Y; Shin T; Curiel TJ; Zhang B
J Clin Invest; 2011 Jun; 121(6):2371-82. PubMed ID: 21537079
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
4. CD73-deficient mice are resistant to carcinogenesis.
Stagg J; Beavis PA; Divisekera U; Liu MC; Möller A; Darcy PK; Smyth MJ
Cancer Res; 2012 May; 72(9):2190-6. PubMed ID: 22396496
[TBL] [Abstract][Full Text] [Related]
5. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
7. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice.
Burghoff S; Gong X; Viethen C; Jacoby C; Flögel U; Bongardt S; Schorr A; Hippe A; Homey B; Schrader J
BMC Cancer; 2014 Dec; 14():898. PubMed ID: 25465225
[TBL] [Abstract][Full Text] [Related]
8. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
10. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
12. CD73 plays a protective role in collagen-induced arthritis.
Chrobak P; Charlebois R; Rejtar P; El Bikai R; Allard B; Stagg J
J Immunol; 2015 Mar; 194(6):2487-92. PubMed ID: 25681339
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.
Teng MW; von Scheidt B; Duret H; Towne JE; Smyth MJ
Cancer Res; 2011 Mar; 71(6):2077-86. PubMed ID: 21282337
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
15. CD73: a potent suppressor of antitumor immune responses.
Beavis PA; Stagg J; Darcy PK; Smyth MJ
Trends Immunol; 2012 May; 33(5):231-7. PubMed ID: 22487321
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
17. IFN-beta protects from vascular leakage via up-regulation of CD73.
Kiss J; Yegutkin GG; Koskinen K; Savunen T; Jalkanen S; Salmi M
Eur J Immunol; 2007 Dec; 37(12):3334-8. PubMed ID: 18034430
[TBL] [Abstract][Full Text] [Related]
18. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
19. Immune regulation of metastasis from in vivo derived syngeneic murine melanoma.
Harning R; Koo GC; Szalay J
Reg Immunol; 1990; 3(2):97-102. PubMed ID: 1965137
[TBL] [Abstract][Full Text] [Related]
20. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
